X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-25 | BMRN | Biomarin Pharmaceutical Inc | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | S - Sale+OE | $115.70 | -49,000 | 41,088 | -54% | -$5,669,134 | |||||
| DM | 2023-01-26 | PLRX | Pliant Therapeutics, Inc. | Coulie Bernard | Pres, CEO | S - Sale+OE | $35.32 | -55,000 | 649,429 | -8% | -$1,942,336 | |||||
| M | 2023-01-25 | GLYC | Glycomimetics Inc | Sandell Scott D | 10% | S - Sale | $3.14 | -3,652,016 | 4,967,530 | -42% | -$11,484,515 | |||||
2023-01-26 | MTCR | Metacrine, Inc. | York Michael | Chief Business Officer | S - Sale | $0.41 | -107,054 | 103,499 | -51% | -$44,331 | ||||||
2023-01-26 | MTCR | Metacrine, Inc. | Klassen Preston | Pres, CEO | S - Sale | $0.41 | -380,605 | 541,905 | -41% | -$157,266 | ||||||
2023-01-25 | CRNX | Crinetics Pharmaceuticals, Inc. | Betz Stephen F. | Chief Scientific Officer | S - Sale | $21.07 | -8,336 | 67,815 | -11% | -$175,640 | ||||||
2023-01-26 | GBIO | Generation Bio Co. | Paone Antoinette | COO | S - Sale | $5.56 | -2,695 | 0 | -100% | -$14,984 | ||||||
| DM | 2023-01-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Lee Yuchun | Dir | S - Sale+OE | $316.15 | -8,000 | 1,875 | -81% | -$2,529,174 | |||||
2023-01-25 | KZR | Kezar Life Sciences, Inc. | Morningside Venture Investments Ltd | 10% | S - Sale | $6.85 | -50,000 | 5,662,993 | -1% | -$342,500 | ||||||
2023-01-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | CEO, Pres | S - Sale | $315.05 | -10,000 | 89,598 | -10% | -$3,150,500 | ||||||
| M | 2023-01-25 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $4.24 | +236 | 513,564 | 0% | +$1,001 | |||||
2023-01-26 | CMRX | Chimerix Inc | Jakeman David | Principal Accounting Officer | S - Sale | $1.76 | -3,230 | 136,752 | -2% | -$5,686 | ||||||
| D | 2023-01-24 | CTIC | Cti Biopharma Corp | Craig Adam R | Pres, CEO | S - Sale+OE | $6.00 | -85,317 | 29,440 | -74% | -$511,923 | |||||
| D | 2023-01-24 | CTIC | Cti Biopharma Corp | Fong James K | EVP, Chief Commercial Officer | S - Sale+OE | $6.00 | -100,000 | 3,565 | -97% | -$600,000 | |||||
| DM | 2023-01-24 | UTHR | United Therapeutics Corp | Rothblatt Martine A | Chairperson, CEO | S - Sale+OE | $261.88 | -16,000 | 644,479 | -2% | -$4,190,116 | |||||
2023-01-24 | PTCT | Ptc Therapeutics, Inc. | Peltz Stuart Walter | CEO | S - Sale | $47.45 | -284 | 55,204 | -1% | -$13,476 | ||||||
2023-01-24 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | Chief Business Officer | S - Sale | $47.45 | -359 | 65,912 | -1% | -$17,035 | ||||||
2023-01-24 | PTCT | Ptc Therapeutics, Inc. | Hill Emily Luisa | CFO | S - Sale | $47.45 | -223 | 46,863 | 0% | -$10,582 | ||||||
2023-01-24 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | Chief Technical Ops Officer | S - Sale | $47.45 | -44 | 3,287 | -1% | -$2,088 | ||||||
| M | 2023-01-24 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, Chief Accounting Officer | S - Sale | $21.86 | -1,097 | 34,836 | -3% | -$23,976 | |||||
2023-01-24 | TVTX | Travere Therapeutics, Inc. | Rote William E. | SVP, R, D | S - Sale | $21.50 | -2,062 | 42,376 | -5% | -$44,333 | ||||||
2023-01-24 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | SVP, GC, Corporate Secretary | S - Sale | $21.50 | -2,062 | 39,776 | -5% | -$44,333 | ||||||
2023-01-24 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale | $21.50 | -6,442 | 147,846 | -4% | -$138,503 | ||||||
2023-01-24 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $21.90 | -852 | 32,871 | -3% | -$18,663 | ||||||
2023-01-24 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Chief Commercial Officer | S - Sale | $21.90 | -1,550 | 63,598 | -2% | -$33,952 | ||||||
2023-01-24 | RAPT | Rapt Therapeutics, Inc. | Ho William | Chief Medical Officer | S - Sale | $30.00 | -5,000 | 30,072 | -14% | -$150,000 | ||||||
2023-01-25 | GALT | Galectin Therapeutics Inc | Eldred Kary | Dir | P - Purchase | $1.11 | +1,300 | 50,640 | +3% | +$1,443 | ||||||
2023-01-25 | TOVX | Theriva Biologics, Inc. | Shallcross Steven A | CEO, CFO | P - Purchase | $0.87 | +25,000 | 160,000 | +19% | +$21,825 | ||||||
| DM | 2023-01-23 | PLRX | Pliant Therapeutics, Inc. | Coulie Bernard | Pres, CEO | S - Sale+OE | $33.12 | -60,000 | 528,129 | -10% | -$1,987,473 | |||||
| D | 2023-01-23 | PLRX | Pliant Therapeutics, Inc. | Ouimette Mike | GC, Corp. Sec'y | S - Sale+OE | $34.19 | -20,000 | 5,947 | -77% | -$683,878 | |||||
2023-01-23 | PLRX | Pliant Therapeutics, Inc. | Lefebvre Eric | Chief Medical Officer | S - Sale | $34.48 | -67,500 | 76,926 | -47% | -$2,327,630 | ||||||
| D | 2023-01-23 | PLRX | Pliant Therapeutics, Inc. | Cummings Keith Lamont | CFO | S - Sale+OE | $35.00 | -30,000 | 84,424 | -26% | -$1,050,000 | |||||
| M | 2023-01-23 | KZR | Kezar Life Sciences, Inc. | Morningside Venture Investments Ltd | 10% | S - Sale | $6.90 | -160,000 | 5,712,993 | -3% | -$1,103,200 | |||||
2023-01-23 | VAXX | Vaxxinity, Inc. | Prime Movers Lab Fund I LP | 10% | S - Sale | $3.35 | -500,692 | 16,754,036 | -3% | -$1,678,019 | ||||||
| DM | 2023-01-23 | TXMD | Therapeuticsmd, Inc. | Donegan Michael C | Prin. Fin., Acctg. Officer | S - Sale+OE | $5.34 | -1,309 | 7,610 | -15% | -$6,988 | |||||
2023-01-23 | ZYNE | Zynerba Pharmaceuticals, Inc. | Sebree Terri B | Pres | S - Sale | $0.60 | -24,661 | 513,204 | -5% | -$14,742 | ||||||
2023-01-23 | ZYNE | Zynerba Pharmaceuticals, Inc. | Fickenscher James E | CFO | S - Sale | $0.60 | -17,769 | 324,736 | -5% | -$10,622 | ||||||
2023-01-23 | ZYNE | Zynerba Pharmaceuticals, Inc. | Rosenberger Brian | VP, Commercial, Business Dev. | S - Sale | $0.60 | -12,663 | 214,848 | -6% | -$7,570 | ||||||
2023-01-23 | ZYNE | Zynerba Pharmaceuticals, Inc. | Anido Armando | COB, Chief Exec. Officer | S - Sale | $0.60 | -35,453 | 866,127 | -4% | -$21,194 | ||||||
2023-01-24 | FOLD | Amicus Therapeutics, Inc. | Rosenberg Ellen | GC | S - Sale | $13.32 | -31,839 | 347,345 | -8% | -$424,006 | ||||||
2023-01-23 | CTLT | Catalent, Inc. | Hopson Ricky | Pres Clinical Dev Supply Div | S - Sale | $49.36 | -643 | 16,452 | -4% | -$31,738 | ||||||
2023-01-23 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $5.00 | +9,900 | 21,536,510 | 0% | +$49,494 | ||||||
2023-01-23 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $5.00 | +9,900 | 21,536,510 | 0% | +$49,494 | ||||||
2023-01-23 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $5.00 | +9,900 | 21,536,510 | 0% | +$49,494 | ||||||
2023-01-23 | NGM | Ngm Biopharmaceuticals Inc | Goeddel David V | Dir, 10% | P - Purchase | $5.00 | +9,900 | 21,797,510 | 0% | +$49,494 | ||||||
2023-01-23 | APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | S - Sale | $51.58 | -2,955 | 37,709 | -7% | -$152,419 | ||||||
2023-01-23 | APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | S - Sale | $51.58 | -4,479 | 47,718 | -9% | -$231,027 | ||||||
| DM | 2023-01-23 | VRTX | Vertex Pharmaceuticals Inc / Ma | Lee Yuchun | Dir | S - Sale+OE | $312.46 | -6,129 | 1,875 | -77% | -$1,915,044 | |||||
2023-01-20 | BTAI | Bioxcel Therapeutics, Inc. | Yocca Frank | Chief Scientific Officer | S - Sale | $30.00 | -50,000 | 8,397 | -86% | -$1,500,000 | ||||||
| D | 2023-01-20 | BTAI | Bioxcel Therapeutics, Inc. | O'Neill Vincent | Chief Medical Officer | S - Sale+OE | $30.00 | -29,713 | 0 | -100% | -$891,390 | |||||
| D | 2023-01-23 | VTYX | Ventyx Biosciences, Inc. | White William Richard | Dir | S - Sale+OE | $35.10 | -33,353 | 0 | -100% | -$1,170,592 | |||||
2023-01-24 | DCPH | Deciphera Pharmaceuticals, Inc. | Brightstar Associates LLC | 10% | P - Purchase | $18.00 | +1,666,666 | 19,718,014 | +9% | +$29,999,988 | ||||||
2023-01-23 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | CEO | S - Sale | $22.00 | -12,500 | 1,744,634 | -1% | -$274,988 | ||||||
2023-01-20 | FULC | Fulcrum Therapeutics, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $13.00 | +1,923,076 | 11,609,704 | +20% | +$24,999,988 | ||||||
| DM | 2023-01-20 | UTHR | United Therapeutics Corp | Rothblatt Martine A | Chairperson, CEO | S - Sale+OE | $259.79 | -16,000 | 644,479 | -2% | -$4,156,674 | |||||
2023-01-20 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $17.37 | +1,500 | 2,732,886 | 0% | +$26,055 | ||||||
| M | 2023-01-19 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | 10% | P - Purchase | $9.70 | +307,500 | 9,887,473 | +3% | +$2,982,733 | |||||
2023-01-20 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | COO, CFO, Secretary | S - Sale | $22.75 | -10,000 | 268,810 | -4% | -$227,523 | ||||||
2023-01-20 | RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | S - Sale | $31.00 | -1,000 | 57,877 | -2% | -$31,000 | ||||||
| D | 2023-01-23 | EVLO | Evelo Biosciences, Inc. | Carriere Stephen J | Principal Accounting Officer | S - Sale+OE | $1.06 | -151 | 203 | -43% | -$160 | |||||
2023-01-23 | ALBO | Albireo Pharma, Inc. | Stephenson Pamela | Chief Commercial Officer | S - Sale | $43.80 | -102 | 42,755 | 0% | -$4,468 | ||||||
2023-01-23 | ALBO | Albireo Pharma, Inc. | Graham Michelle | CHRO | S - Sale | $43.80 | -102 | 24,493 | 0% | -$4,468 | ||||||
2023-01-23 | ALBO | Albireo Pharma, Inc. | Mattsson Jan | Chief Scientific Officer | S - Sale | $43.80 | -197 | 54,474 | 0% | -$8,629 | ||||||
2023-01-23 | ALBO | Albireo Pharma, Inc. | Harford Simon N.R. | CFO, Treasurer | S - Sale | $43.80 | -102 | 32,689 | 0% | -$4,468 | ||||||
2023-01-23 | ALBO | Albireo Pharma, Inc. | Duncan Jason | GC, GC | S - Sale | $43.80 | -228 | 14,146 | -2% | -$9,986 | ||||||
2023-01-23 | ALBO | Albireo Pharma, Inc. | Cooper Ronald Harold Wilfred | Pres, CEO | S - Sale | $43.80 | -1,057 | 57,444 | -2% | -$46,297 | ||||||
2023-01-23 | CNTX | Context Therapeutics Inc. | Lehr Martin A. | CEO | P - Purchase | $0.72 | +6,839 | 956,395 | +1% | +$4,901 | ||||||
2023-01-23 | ALBO | Albireo Pharma, Inc. | Carter Martha J. | Chief Regulatory Officer | S - Sale | $43.80 | -120 | 14,506 | -1% | -$5,256 | ||||||
| M | 2023-01-19 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $5.00 | +38,139 | 21,526,610 | 0% | +$190,603 | |||||
| M | 2023-01-19 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $5.00 | +38,139 | 21,526,610 | 0% | +$190,603 | |||||
2023-01-19 | MGNX | Macrogenics Inc | Biotech Target N V | 10% | P - Purchase | $5.30 | +150,000 | 9,079,963 | +2% | +$794,925 | ||||||
| M | 2023-01-19 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $5.00 | +38,139 | 21,526,610 | 0% | +$190,603 | |||||
| M | 2023-01-19 | NGM | Ngm Biopharmaceuticals Inc | Goeddel David V | Dir, 10% | P - Purchase | $5.00 | +38,139 | 21,787,610 | 0% | +$190,603 | |||||
| D | 2023-01-18 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | See Remarks | S - Sale+OE | $14.03 | -10,000 | 67,600 | -13% | -$140,300 | |||||
2023-01-20 | TOVX | Theriva Biologics, Inc. | Shallcross Steven A | CEO, CFO | P - Purchase | $0.75 | +25,000 | 135,000 | +23% | +$18,705 | ||||||
| D | 2023-01-18 | PRTA | Prothena Corp Public Ltd Co | Nguyen Tran | Chief Strategy Officer, CFO | S - Sale+OE | $55.53 | -10,000 | 3,200 | -76% | -$555,306 | |||||
| D | 2023-01-18 | PRVB | Provention Bio, Inc. | Palmer Ashleigh | Dir, CEO | S - Sale+OE | $10.27 | -24,165 | 2,570,050 | -1% | -$248,063 | |||||
| D | 2023-01-18 | PRVB | Provention Bio, Inc. | Leon Francisco | Chief Scientific Officer | S - Sale+OE | $10.27 | -24,015 | 2,573,000 | -1% | -$246,584 | |||||
| D | 2023-01-20 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Pres, Chief Exec | S - Sale+OE | $8.20 | -5,821 | 179,043 | -3% | -$47,729 | |||||
2023-01-19 | RAPT | Rapt Therapeutics, Inc. | Ho William | Chief Medical Officer | S - Sale | $25.56 | -5,000 | 35,072 | -12% | -$127,800 | ||||||
| D | 2023-01-18 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $40.40 | -4,936 | 1,842,017 | 0% | -$199,394 | |||||
2023-01-18 | MYOV | Myovant Sciences Ltd. | Lang Matthew | GC, Corp. Secy. | S - Sale | $26.89 | -1,272 | 354,303 | 0% | -$34,204 | ||||||
2023-01-18 | MYOV | Myovant Sciences Ltd. | Merendino Lauren | Chief Commercial Officer | S - Sale | $26.89 | -2,008 | 169,538 | -1% | -$53,995 | ||||||
2023-01-18 | MYOV | Myovant Sciences Ltd. | Marek David C | Principal Exec Officer | S - Sale | $26.89 | -8,037 | 417,599 | -2% | -$216,115 | ||||||
2020-04-13 | KROS | Keros Therapeutics, Inc. | Knowles Julius | Dir | P - Purchase | $20.98 | +1,191 | 575,492 | 0% | +$24,987 | ||||||
2023-01-20 | CLSD | Clearside Biomedical, Inc. | Ciulla Thomas | Chief Medical Officer | S - Sale | $1.47 | -13,700 | 291,890 | -4% | -$20,139 | ||||||
2023-01-18 | MYOV | Myovant Sciences Ltd. | Arjona Ferreira Juan Camilo | Chief Medical Officer | S - Sale | $26.89 | -1,109 | 246,684 | 0% | -$29,821 | ||||||
2023-01-19 | CLSD | Clearside Biomedical, Inc. | Lasezkay George M | CEO | S - Sale | $1.46 | -20,030 | 484,577 | -4% | -$29,244 | ||||||
| DM | 2023-01-18 | UTHR | United Therapeutics Corp | Rothblatt Martine A | Chairperson, CEO | S - Sale+OE | $259.83 | -16,000 | 644,479 | -2% | -$4,157,221 | |||||
2023-01-19 | CLSD | Clearside Biomedical, Inc. | Deignan Charles A. | CFO | S - Sale | $1.50 | -14,030 | 363,472 | -4% | -$21,045 | ||||||
2023-01-18 | PRVB | Provention Bio, Inc. | Sessa Capital (Master), L.P. | 10% | S - Sale | $9.40 | -3,000,000 | 11,879,023 | -20% | -$28,200,000 | ||||||
2023-01-19 | ALBO | Albireo Pharma, Inc. | Carter Martha J. | Chief Regulatory Officer | S - Sale | $43.90 | -938 | 14,626 | -6% | -$41,182 | ||||||
2023-01-19 | ALBO | Albireo Pharma, Inc. | Duncan Jason | GC, GC | S - Sale | $43.90 | -938 | 14,374 | -6% | -$41,182 | ||||||
2023-01-19 | ALBO | Albireo Pharma, Inc. | Stephenson Pamela | Chief Commercial Officer | S - Sale | $43.90 | -1,774 | 42,857 | -4% | -$77,886 | ||||||
2023-01-19 | ALBO | Albireo Pharma, Inc. | Mattsson Jan | Chief Scientific Officer | S - Sale | $43.80 | -3,088 | 54,671 | -5% | -$135,254 | ||||||
2023-01-19 | ALBO | Albireo Pharma, Inc. | Graham Michelle | CHRO | S - Sale | $43.90 | -1,774 | 24,595 | -7% | -$77,886 | ||||||
2023-01-19 | ALBO | Albireo Pharma, Inc. | Harford Simon N.R. | CFO, Treasurer | S - Sale | $43.80 | -1,776 | 32,791 | -5% | -$77,789 | ||||||
| D | 2023-01-18 | QURE | Uniqure N.V. | Soteropoulos Paula | Dir | S - Sale+OE | $22.59 | -6,000 | 16,382 | -27% | -$135,540 | |||||
2023-01-18 | MRTX | Mirati Therapeutics, Inc. | Cherrington Julie M | Dir | S - Sale | $44.66 | -2,546 | 0 | -100% | -$113,704 | ||||||
| D | 2023-01-17 | RXDX | Prometheus Biosciences, Inc. | Marshall Keith W | CFO | S - Sale+OE | $119.00 | -5,000 | 9,811 | -34% | -$595,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |